The potent immunosuppressive and injury‐mitigating effects of the MEK inhibitor Mek162 indicate that targeting the CXCR1/MEK1/ERK signaling axis is an effective strategy to restore the Th17/Treg balance in ALI, which provides evidence for exploring novel treatments. This evidence concerns the gene MAP2K1 and acute respiratory distress syndrome.